Fig. 3

Chemoprotection of primary murine hematopoietic progenitor cells genetically engineered with MDR1 and CDD. Gene-modified lin⁻ hematopoietic progenitor cells were applied to a clonogenic progenitor assay. a LV.SFFV.MDR1 as well as LV.SFFV.GFP gene-modified cells were treated with daunorubicin monotherapy (n = 3), (b) LV.SFFV.CDD as well as LV.SFFV.GFP transduced cells were treated with Ara-C monotherapy (n = 3) and (c) LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP gene-modified cells were treated with daunorubicin/Ara-C combination therapy (n = 4). Data are presented as mean ± SEM; *p ≤ 0.05/** p ≤ 0.01 denote significant differences compared to LV.SFFV.GFP control (calculated by ANOVA)